jRCT1030250817RecruitingNot Applicable
Safety of Combined Use of ARISTA AH and AdSpray on the Liver Resection Surface: A Clinical Study
Not provided0 sites100 target enrollmentStarted: TBD
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Enrollment
- 100
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Single Arm Study
Eligibility Criteria
- Ages
- 18age old over to No limit (—)
- Sex
- All
Inclusion Criteria
- •Patients who meet all of the following criteria will be included:
- •Patients with primary or metastatic liver tumors (hepatocellular carcinoma, intrahepatic cholangiocarcinoma, or metastatic liver cancer) who are clinically indicated for liver resection based on liver function and tumor characteristics
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- •3.Age 18 years or older, regardless of sex
Exclusion Criteria
- •Patients meeting any of the following criteria will be excluded:
- •Patients undergoing liver resection requiring vascular or biliary reconstruction
- •Patients with intrahepatic cholangiocarcinoma requiring lymph node dissection
- •Patients with impaired liver function (Child-Pugh class B or C)
- •Patients with tumor invasion to adjacent organs (excluding the gallbladder)
- •Patients with tumor invasion into the inferior vena cava
- •Patients deemed unsuitable for participation in this study by the principal investigator
- •Patients who decline to participate in this study
Investigators
Similar Trials
Completed
Phase 2
A study to investigate safety and efficacy with SAR445514 in participants with relapsed/refractory multiple myeloma (RRMM) and relapsed/refractory light-chain amyloidosis (RRLCA)2022-502057-33-00Sanofi-Aventis Recherche & Developpement59
Recruiting
Phase 1
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7806881 in Healthy ParticipantsNCT07271693Hoffmann-La Roche128
Completed
Phase 1
Safety and tolerability of single and multiple ascending doses of lunsekimig (SAR443765) in healthy participantsAsthma2023-509316-28-00Sanofi-Aventis Recherche & Developpement128
Recruiting
Not Applicable
Effect of Simultaneous Injection of Contrast Material and Saline on Image Quality in Contrast-Enhanced CTAll conditions requiring body contrast-enhanced CTjRCT1042250201200
Recruiting
Phase 1
A study to determine the safety and effect of antibodies against hepatitis D (the SAMBA-D study)2025-522125-36-00Region Midtjylland15